Korean biopharmaceutical companies continue to gain R&D achievements for targeted anti-cancer drugs. Companies have prepared to present their Korean-made anti-cancer drugs, including Leclaza and Rivoceranib at the 2024 World Conference on Lung Cancer, which will be held September 7-10 in San Diego, USA.

Yuhan Pharmaceutical will present the clinical results comparing the efficacy of its proprietary Leclaza monotherapy, a non-small cell lung cancer (NSCLC) treatment, to Tagrisso. This month, Leclaza plus Rybrevant combination therapy passed the U.S. Food and Drug Administration (FDA) approval. A shift in the market for the first-line treatment of EGFR-positive NSCLC is expected if Leclaza monotherapy o